Polyneuropathies Clinical Trial
Official title:
The Impact of Early Treatment With IgM-enriched IVIG on Critical Illness Polyneuropathy and/or Myopathy in Patients With Multiple Organ Failure and SIRS/Sepsis: A Prospective, Randomized, Placebo-controlled, Double-blinded Trial
Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective was to assess the effect of early IgM-enriched IVIG versus placebo to mitigate CIPNM in a prospective setting.
Background: Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication
of critical illness. Retrospective data suggest that early application of IgM-enriched
intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary
objective will be to assess the effect of early IgM-enriched IVIG versus placebo to mitigate
CIPNM in a prospective setting.
Design: Prospective, randomized, double-blinded and placebo-controlled trial
Setting: Eight-bed medical ICU of a university hospital.
Participants: Critically ill patients will be screened for eligibility defined as multiple
organ failure (MOF) and SIRS/sepsis. Patients fulfilling these criteria will be further
assessed by a neurologist for clinical signs of CIPNM.
Critically ill patients with multiple organ failure (MOF), SIRS/sepsis, and early clinical
signs of CIPNM will be randomized.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06040567 -
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
|
||
Enrolling by invitation |
NCT04461613 -
Physical Activity in Persons With Charcot-Marie-Tooth: Developing a Measurement Instrument
|
N/A | |
Enrolling by invitation |
NCT06359561 -
Assessment of Effectiveness and Stimulation Coverage of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy in Patients With Cervical Lead Placement
|
||
Recruiting |
NCT06044662 -
Prognostic Value of Biomarkers in Polyneuropathy.
|
||
Completed |
NCT00050245 -
Rituximab to Treat Neuropathy With Anti-MAG Antibodies
|
Phase 2 | |
Not yet recruiting |
NCT01718015 -
Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy
|
N/A | |
Completed |
NCT03765489 -
Electrical Muscle Stimulation in the Development of Acquired Weakness in Patients With Severe Sepsis and Septic Shock
|
N/A | |
Completed |
NCT01370837 -
Neurogenic Inflammation in Diabetes
|
N/A | |
Not yet recruiting |
NCT02061059 -
Cost-effectiveness of In-shoe Pressure Measurement for Therapeutic Shoes
|
N/A | |
Recruiting |
NCT06377033 -
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
|
N/A | |
Not yet recruiting |
NCT06390527 -
Ultrasonography in Diagnosis of Polyneuropathy
|
||
Recruiting |
NCT05188690 -
Polyneuropathy and COVID-19
|
||
Completed |
NCT00231673 -
A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy
|
Phase 2 | |
Recruiting |
NCT03237494 -
TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
|
||
Active, not recruiting |
NCT03617185 -
Effect of Exercise and Surgical Weight Loss on Polyneuropathy
|
N/A | |
Active, not recruiting |
NCT02753036 -
Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer
|
||
Completed |
NCT01263132 -
Neuropathic Pain Management
|
Phase 3 | |
Completed |
NCT00162968 -
Escitalopram as a Treatment for Pain in Polyneuropathy
|
Phase 4 | |
Completed |
NCT04664426 -
Sensory Neuropathy Scores Validated by Quantitative Sensory Testing and Nerve Conduction Studies for Kidney Transplant Recipients
|
||
Recruiting |
NCT05023889 -
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
|
Early Phase 1 |